An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Seres Therapeutics, Inc. (Nasdaq: MCRB) will release its third quarter 2023 financial results on November 2, 2023. A conference call with investors will be held at 8:00 a.m. ET. The webcast replay will be available on the Seres website for approximately 21 days.
Positive
None.
Negative
None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will release third quarter 2023 financial results on Thursday, November 2, 2023. Management will host a conference call with investors to discuss the results and corporate updates at 8:00 a.m. ET.
The conference call may be accessed by calling 1-866-777-2509 (international callers dial 1-412-317-5413). Participants may pre-register for the conference call at https://dpregister.com/sreg/10184132/faf729b9c0
To join the live webcast, please visit the “Investors and News” section of the Seres website at www.serestherapeutics.com.
A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Seres’ lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiome therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. Seres is evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation. The Company is also conducting research to inform further development of microbiome therapeutics for ulcerative colitis. For more information, please visit www.serestherapeutics.com.
When will Seres Therapeutics release its third quarter 2023 financial results?
Seres Therapeutics will release its third quarter 2023 financial results on November 2, 2023.
What is the conference call schedule for Seres Therapeutics?
The conference call with investors will be held at 8:00 a.m. ET.
How can I access the conference call?
The conference call can be accessed by calling 1-866-777-2509 (international callers dial 1-412-317-5413). Participants may also pre-register for the conference call at https://dpregister.com/sreg/10184132/faf729b9c0.
Where can I find the webcast replay?
The webcast replay will be available on the Seres website in the 'Investors and News' section. It will be archived for approximately 21 days.
